The fact that LRRK2‐PD has an almost indistinguishable pathological phenotype from sporadic PD and the presence of a druggable kinase activity within LRRK2 were sufficient reasons for researchers to look at this protein as a potential target for a neuroprotective treatment in PD. The gene discussed is LRRK2; the disease is Parkinson disease.